Full Press Release Details
argenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigimod for Myasthenia Gravis at Upcoming Virtual Medical Meetings.
ARGX
argenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigimod for Myasthenia Gravis at Upcoming Virtual Medical Meetings
Key Takeaway: argenx to Present Additional Data from Global Phase 3 ADAPT Trial of Efgartigimod for Myasthenia Gravis at Upcoming Virtual Medical Meetings
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+36%
120-day peak, hindsight
Typical move
4.7%
average across 12 past catalysts
Lead asset
Empasiprubart
Phase 2 · AChR-Ab Seropositive Generalized Myasthenia Gravis